GLP-1 Drug Exenatide Restores a Key Fat-Signaling Molecule in Rats with Polycystic Ovary Syndrome

Exenatide, a GLP-1 receptor agonist peptide, improved adiponectin signaling in rats with polycystic ovary syndrome (PCOS). PCOS rats showed diminished adiponectin levels and elevated adiponectin receptor 1 (Adipo-R1) mRNA. Treatment with exenatide at both 50 mg/kg and 100 mg/kg doses restored adiponectin expression and normalized Adipo-R1 levels, suggesting the peptide may improve PCOS through molecular regulation of the adiponectin system.

Experimental animal study using 28 female Wistar rats divided into four groups: normal control, PCOS+vehicle, PCOS+exenatide 50 mg/kg, and PCOS+exenatide 100 mg/kg. PCOS was induced with estradiol valerate. Adiponectin and Adipo-R1 mRNA expression was measured using semi-quantitative real-time PCR.

PCOS affects millions of women worldwide and is a leading cause of infertility. Understanding how GLP-1 receptor agonists like exenatide interact with the adiponectin pathway could reveal new therapeutic approaches for managing PCOS beyond its established role in diabetes and weight management.

GLP-1 receptor agonists like exenatide and semaglutide are already transforming diabetes and obesity treatment. This study adds to growing evidence that these peptide drugs may have beneficial effects in PCOS — a condition closely linked to metabolic dysfunction — potentially through their influence on adiponectin, a key metabolic regulator.

This is an animal study with a small sample size (7 rats per group), so results may not directly translate to humans. The study used only mRNA expression as a readout without measuring protein levels or functional outcomes like fertility restoration.